These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 2127223

  • 1. Association between tissue plasminogen activator and serum lipids in healthy volunteers.
    Yamada R, Yamada S, Ishii A, Sasamata M, Watanabe S.
    Ann Med; 1990; 22(5):313-8. PubMed ID: 2127223
    [Abstract] [Full Text] [Related]

  • 2. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease.
    Smith FB, Lee AJ, Rumley A, Fowkes FG, Lowe GD.
    Atherosclerosis; 1995 May; 115(1):35-43. PubMed ID: 7669086
    [Abstract] [Full Text] [Related]

  • 3. [t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction].
    Yamada S, Yamada R, Ishii A, Ashikawa K, Nakamura M, Sasamata M, Watanabe S.
    Rinsho Byori; 1990 Jul; 38(7):819-24. PubMed ID: 2119465
    [Abstract] [Full Text] [Related]

  • 4. Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor.
    Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA.
    Arteriosclerosis; 1989 Jul; 9(6):934-9. PubMed ID: 2511826
    [Abstract] [Full Text] [Related]

  • 5. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
    Akanji AO, Abdullah A, Tahzeeb S.
    Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
    Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y, Ootsuka S, Shinoda T, Yanagi H, Tsuchiya S, Marumo F.
    Am J Kidney Dis; 1996 Jun; 27(6):848-54. PubMed ID: 8651250
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
    Wojta J, Turcu L, Wagner OF, Korninger C, Binder BR.
    J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
    [Abstract] [Full Text] [Related]

  • 9. Effects of high and low intensity aerobic conditioning programs on blood fibrinolysis and lipid profile.
    el-Sayed MS.
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):484-90. PubMed ID: 8840002
    [Abstract] [Full Text] [Related]

  • 10. [The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects].
    Kobayashi Y, Fukuo Y, Shibuya T, Terashi A.
    Nihon Ronen Igakkai Zasshi; 1990 Sep; 27(5):578-83. PubMed ID: 2124638
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
    Gürlek A, Bayraktar M, Kirazli S.
    Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
    [Abstract] [Full Text] [Related]

  • 14. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
    Koh SC, Yuen R, Viegas OA, Chua SE, Ng BL, Sen DK, Ratnam SS.
    Thromb Haemost; 1991 Nov 01; 66(5):581-5. PubMed ID: 1803623
    [Abstract] [Full Text] [Related]

  • 15. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
    Angleton P, Chandler WL, Schmer G.
    Circulation; 1989 Jan 01; 79(1):101-6. PubMed ID: 2491971
    [Abstract] [Full Text] [Related]

  • 16. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.
    Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A.
    Thromb Haemost; 1991 Oct 01; 66(4):474-8. PubMed ID: 1796399
    [Abstract] [Full Text] [Related]

  • 17. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
    Jokaji H, Asakura H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T.
    Nihon Ronen Igakkai Zasshi; 1990 Nov 01; 27(6):699-705. PubMed ID: 2127812
    [Abstract] [Full Text] [Related]

  • 18. Diurnal variation of the fibrinolytic system.
    Grimaudo V, Hauert J, Bachmann F, Kruithof EK.
    Thromb Haemost; 1988 Jun 16; 59(3):495-9. PubMed ID: 3142085
    [Abstract] [Full Text] [Related]

  • 19. Analysis of factors influencing the blood levels and activities of tissue-type plasminogen activator (t-PA).
    Wei R, Han JJ, Bai B, Ren DL, Chen B, Yang MF, Xia ZL.
    Clin Hemorheol Microcirc; 2003 Jun 16; 29(3-4):351-6. PubMed ID: 14724361
    [Abstract] [Full Text] [Related]

  • 20. [Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury].
    Beuth W, Kotschy M, Kasprzak HA, Rość D, Osiński P, Sniegocki M.
    Neurol Neurochir Pol; 1996 Jun 16; 30(3):427-34. PubMed ID: 8965977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.